Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,821 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
₹787 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Biocon's Q3 FY25 results were in line with expectations, with consolidated revenue from operations of INR 3,821 crore, up 10% YoY on a like-for-like basis. Growth was driven by biosimilars (+14% YoY) and research services (+11% YoY), while generics declined marginally (-2% YoY). Core EBITDA margin was healthy at 26%, though reported EBITDA margin stood at 20% due to higher R&D and operating expenses. Key positives include successful FDA inspections at three sites, USFDA approval for biosimilar Ustekinumab (Yesintek) with a February 2025 launch, and EU approval for generic liraglutide. Management maintains a growth outlook for H2 FY25 and FY26, driven by new product launches. However, elevated net debt of $1.3 billion and ongoing pricing pressure in generics remain key risks.
Colored figures show movement against the previous available record.
Guidance to track
- Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.
- First GLP-1 generic will launch in the UK in Q4 FY25, followed by EU national launches in Q1 FY26.
- Generics business expected to return to mid-teens growth in FY26, driven by liraglutide and other launches.
- With VAI status for manufacturing sites, management expects expedited FDA review for these biosimilars.
Risks flagged
- Consolidated net debt stands at ~$1.3 billion, with additional short-term borrowing for stake purchase, increasing financial leverage.
- Generics face persistent pricing pressure, and biosimilars experience price erosion in line with budget, impacting revenue growth relative to volume gains.
- Investors in Biocon Biologics have liquidity options; management did not quantify potential liabilities, creating uncertainty.
- Five US launches in 12 months and global rollouts require flawless regulatory and commercial execution; any delays could impact growth.
Key quotes
- We maintain our outlook for a transition to growth in the second half of this year and into next fiscal with improved visibility across all businesses.
- The only piece that was remaining was the site GMP status. With that achieved, we've responded to them saying that we've now completed this, and we want them to reconsider our application at the earliest.
- I think the Viatris settlement deal was about the deferred payment that we had to work on. And like we've said, we've been able to close out the entire $335 million.
Research modules